The Phase 1/2a study ISO-CC-005 is completed
GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announces that the recruitment and treatment of patients in the company's Phase 1/2a study with arfolitixorin has been completed. Totally 101 patients have been treated at 10 hospitals in the Nordic countries and Europe. The final analysis has started and study data is expected to be presented at ESMO 2020.Ulf Jungnelius, M.D., Chief Executive Officer of Isofol, comments: “ISO-CC-005 has fulfilled its purpose by determining the dose we have chosen for further development in our Global